https://orcid.org/0000-0002-2585-2029
References
- Akinboboye O, Shah K, Warner AL, et al. DISCOVERY: prevalence of transthyretin (TTR) mutations in a US-centric patient population suspected of having cardiac amyloidosis [published online ahead of print, 2020 May 26]. Amyloid. 2020;1–8.doi:10.1080/13506129.2020.1764928.
- Buxbaum J, Ruberg F. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19(7):733–742.
- Lahuerta C, Aibar MA, Gracia A, et al. Estimating the prevalence of allelic variants in the transthyretin gene by analysing large scale sequencing data. Eur J Hum Genet. 2019;27(5):783–791.
- Gentile L, Di Bella G, Minutoli F, et al. Description of a large cohort of caucasian patients with V122I ATTRv amyloidosis: neurological and cardiological features. J Peripher Nerv Syst. 2020;25(3):273–278.
- López-Sainz Á, Hernandez-Hernandez A, Gonzalez-Lopez E, et al. Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center [published online ahead of print, 2020 Apr 18]. Rev Esp Cardiol (Engl Ed). 2020;S1885-5857(20)30098-0. English, Spanish. doi:10.1016/j.rec.2019.12.020.